Osteosarcoma (OS) is the most common primary malignant tumor of bone. Thanks to its high heterogeneity and to survival signals from bone microenvironment, OS can resist to current standard treatments and for this reason, novel therapies are needed. Literature data assert that c-MET oncogene, a tyrosine-kinase receptor, plays a crucial role in OS initiation and progression. In the present study, we aimed to evaluate the effect of c-MET inhibitor cabozantinib (CBZ) on OS both directly and through its action on bone microenvironment. We tested different doses of CBZ on in vitro models of OS alone or in co-culture with bone cells in order to reproduce OS-tumor microenvironment interactions. We demonstrated that CBZ is able to decrease proliferation and migration of OS cells, inhibiting ERK and AKT signalling pathways. As a consequence, OS cells activate autophagic process. Furthermore, CBZ leads to a further inhibition of the proliferation of OS cells expressing receptor activator of nuclear factor ?B (RANK), thanks to its effect on bone microenvironment, where it causes an overproduction of osteoprotegerin and a decrease of production of RANK ligand by osteoblasts. Overall, our data demonstrate that CBZ might represent a new potential treatment against OS, affecting both OS cells and their microenvironment. In this scenario, RANK expression in OS cells could represent a predictive factor of better response to CBZ treatment.

Valutazione dell'effetto antitumorale di Cabozantinib sull'osteosarcoma e sul microambiente osseo / Marco Fioramonti - : . , 2016 Jul 29. ((28. ciclo

Valutazione dell'effetto antitumorale di Cabozantinib sull'osteosarcoma e sul microambiente osseo

2016-07-29

Abstract

Osteosarcoma (OS) is the most common primary malignant tumor of bone. Thanks to its high heterogeneity and to survival signals from bone microenvironment, OS can resist to current standard treatments and for this reason, novel therapies are needed. Literature data assert that c-MET oncogene, a tyrosine-kinase receptor, plays a crucial role in OS initiation and progression. In the present study, we aimed to evaluate the effect of c-MET inhibitor cabozantinib (CBZ) on OS both directly and through its action on bone microenvironment. We tested different doses of CBZ on in vitro models of OS alone or in co-culture with bone cells in order to reproduce OS-tumor microenvironment interactions. We demonstrated that CBZ is able to decrease proliferation and migration of OS cells, inhibiting ERK and AKT signalling pathways. As a consequence, OS cells activate autophagic process. Furthermore, CBZ leads to a further inhibition of the proliferation of OS cells expressing receptor activator of nuclear factor ?B (RANK), thanks to its effect on bone microenvironment, where it causes an overproduction of osteoprotegerin and a decrease of production of RANK ligand by osteoblasts. Overall, our data demonstrate that CBZ might represent a new potential treatment against OS, affecting both OS cells and their microenvironment. In this scenario, RANK expression in OS cells could represent a predictive factor of better response to CBZ treatment.
Osteosarcoma; Microambiente Osseo; c-MET; Cabozantinib; RANK
Valutazione dell'effetto antitumorale di Cabozantinib sull'osteosarcoma e sul microambiente osseo / Marco Fioramonti - : . , 2016 Jul 29. ((28. ciclo
File in questo prodotto:
File Dimensione Formato  
DT_157_FioramontiMarco.pdf

accesso aperto

Tipologia: Tesi di dottorato
Licenza: Creative commons
Dimensione 4.06 MB
Formato Adobe PDF
4.06 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12610/68780
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact